NHNarciso Hernández-Toriz

Narciso Hernández-Toriz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Narciso Hernández-Toriz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    [First cohort: Robotic radical prostatectomy at the Mexican Institute for Social Security].

    by Seiichi Fuziwara-Ruíz, Narciso Hernández-Toriz, Juan Carlos Huerta-Gómez, Joel Quintero-Becerra, Andrés Martínez-Cornelio, Juan Carlos Zapot-Martínez, Arturo Delgado-Herrera, Cristobal Castro-Chávez, Oscar Pérez-Ramírez

    Prostate cancer is the most common cancer in men and the leading cause of malignancy-related mortality in Mexico. The Mexican Institute for Social Security (IMSS for its initialism in Spanish) introduced its first robotic system at the Oncology Hospital of the 21st Century National Medical Center in Mexico City. To evaluate the accumulated experience, perioperative, oncologic and functional outcomes of the first 200 robot-assisted radical prostatectomy (RARP) cases. A retrospective analysis of 200 patients undergoing RARP for localized prostate cancer was conducted. Perioperative and postoperative variables, pathology results, complications, and one-year continence rates were considered. Mean surgical time was 242.1 minutes (90-600), with a console time of 197.6 minutes (68-495). Mean blood loss was 327.7 cc (10-1800). Positive surgical margins were observed in 34.5% of cases. Complications occurred in 22 patients (11%). No conversions to open surgery or mortality were reported. Mean hospital stay was 2.54 days (2-14). Postoperative antigen was undetectable in 88.5% of patients. The continence rate was 95.7%. The first 200 RARP cases at our institution demonstrate the accumulated experience with the procedure, showing low complication rates. These results are consistent with those of high-volume centers, which require additional long-term functional follow-up.

  • Open Access

    Utilidad del 18-FDG-PET/CT para determinar viabilidad tumoral en manejo de masas residuales de seminoma posquimioterapia

    by Efraín Mamani-Flores, Narciso Hernández-Toriz, Juan Carlos Huerta-Gómez, Joel Quintero-Becerra, Vianey Brígida Ayala-Quispe

    Background: Post-chemotherapy management of seminoma has evolved in recent decades due to the increasing use of positron emission tomography with 18 fluoro-deoxy-D-glucose (18-FDG-PET) this method alone or combined with computed tomography (CT). It has been proposed as a non-invasive tool to assess the extent of the disease. The objective was to determine its usefulness to determine tumor viability in the management of residual retroperitoneal masses of post-chemotherapy seminoma. Material and Methods: Monocentric retrospective study, clinical records of 53 patients were reviewed during 2013-2018. Response to treatment was defined by Recist 1.1 criteria by CT and tumor viability by Suv Max by 18-FDG-PET / CT. According to the results, it was divided into groups: surveillance (group 1), rescue surgery (group 2), radiotherapy (group 3) and chemotherapy (group 4). Descriptive statistics were performed with the SPSS v24 program. ROC curve was used to define cut point, sensitivity (S) and specificity (E). Results: When analyzing, without discriminating by groups, an ROC curve with a cut-off point of 3.150, S 50% and E 60% was found, values that are neither discriminatory nor useful to define tumor viability. When analyzing the group of surveillance and rescue surgery, S 80% and E 82% were obtained. When compared with groups 3 and 4, they had a cut-off point of 3,150 and 2,350, respectively. Conclusions: First study carried out in the country, the 18 FDG-PET / CT demonstrated a very poor utility for discriminating tumor viability in post-chemotherapy seminomatous residual masses, improving the results for the rescue and surveillance groups.

  • Open Access

    Utilidad del 18-FDG-PET/CT para determinar viabilidad tumoral en manejo de masas residuales de seminoma posquimioterapia

    by Efraín Mamani-Flores, Narciso Hernández-Toriz, Juan Carlos Huerta-Gómez, Joel Quintero-Becerra, Vianey Brígida Ayala-Quispe

    Antecedentes: En las últimas décadas, el manejo postquimioterapia de seminoma ha evolucionado debido al uso creciente de tomografía por emisión de positrones con 18 fluoro-desoxi-D-glucosa (18-FDG-PET) este método solo o combinado con la tomografía computarizada (CT) se ha propuesto como herramienta no invasiva para evaluar la extensión de la enfermedad. El objetivo fue conocer su utilidad para determinar viabilidad tumoral en el manejo de masas residuales retroperitoneales de seminoma postquimioterapia. Material y Métodos: Estudio retrospectivo monocéntrico, se revisaron expedientes clínicos de 53 pacientes durante 2013-2018. Se definió respuesta a tratamiento mediante criterios de Recist 1.1 por CT y viabilidad tumoral mediante Suv Max por 18-FDG-PET/CT. Según resultado se dividió en grupos: vigilancia (grupo 1), cirugía de rescate (grupo 2), radioterapia (grupo 3) y quimioterapia (grupo 4). Se realizo estadística descriptiva con programa SPSS v24. Se uso curva ROC para definir punto de corte, sensibilidad (S) y especificidad (E). Resultados: Al analizar, sin discriminar por grupos, se encontró una curva ROC con punto de corte de 3.150, S 50% y E 60%, valores que no son discriminativos ni útiles para definir viabilidad tumoral. Al analizar el grupo de vigilancia y cirugía de rescate se obtuvieron S 80% y E 82%. Al comparar con los grupos 3 y 4 tuvieron un punto de corte de 3.150 y 2.350 respectivamente. Conclusiones: Primer estudio realizado en el país, el 18 FDG-PET/CT demostró una utilidad muy pobre para discriminar viabilidad tumoral en masas residuales seminomatosas postquimioterapia, mejorando discretamente los resultados para los grupos de vigilancia y cirugía de rescate.